vimarsana.com
Home
Live Updates
Kamada Announces Kedrion Exercised its Option for Two-Year E
Kamada Announces Kedrion Exercised its Option for Two-Year E
Kamada Announces Kedrion Exercised its Option for Two-Year Extension of KEDRAB® Distribution Agreement in the U.S.
The Extended Agreement Term is Until March 2026The Company Generated Approximately $16 Million in Revenue from Sales of KEDRAB to Kedrion in 2022 and Anticipates a Significant Increase in 2023 ...
Related Keywords
United States ,
Brazil ,
Canada ,
India ,
Texas ,
Rehovot ,
Hamerkaz ,
Israel ,
Argentina ,
Russia ,
Australia ,
America ,
Israeli ,
Chaime Orlev ,
Brian Ritchie ,
Company Generated ,
Nasdaq ,
Exchange Commission ,
Us Securities Exchange ,
Lifesci Advisors ,
European Medicines Agency ,
Israeli Ministry Of Health ,
Globenewswire Inc ,
Kamada Ltd ,
Extended Agreement Term ,
Significant Increase ,
Rabies Immune Globulin ,
Medicines Agency ,
Exchange Act ,
Securities Litigation Reform Act ,
Annual Report ,
Sci Advisors ,